Capital Pharmacy Pharmaceutical Import Profile — Oman (DGFT 2022–2026)

Name: Capital Pharmacy Pharmaceutical Import Records from India — 2 Products, $2.3M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Capital Pharmacy — Pharmaceutical Importer Profile (2026) | 2 Products, $2.3M Trade | TransData Nexus

Capital Pharmacy

Pharmaceutical Importer · Oman · Gastrointestinal Focus · $2.3M Total Trade · DGFT Verified

Capital Pharmacy is a pharmaceutical importer based in Oman with a total trade value of $2.3M across 2 products in 2 therapeutic categories. Based on 46 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. Capital Pharmacy sources from 3 verified Indian suppliers, with Cipla Limited accounting for 98.6% of imports.

Capital Pharmacy — Import Portfolio & Supplier Network

Capital Pharmacy import network — 2 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Capital Pharmacy?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Cipla Limited	$7.2M	799	98.6%
Strides Pharma Science Limited	$100.4K	4	1.4%
Mankind Pharma Limited	$1.8K

What Formulations Does Capital Pharmacy Import?

Formulation	Value	Ships
Lanzol 30 capsules (lansoprazole 30MG)	$300.0K	6
Budecort 0.5 MG respules/budesonide	$272.1K	6
Azee 500 tablet (azithromycin	$250.0K	5
Flomist nasal spray (fluticasone	$230.5K	6
Prolyte (lime flavour)(oral	$207.6K	10
Foracort 200 inhaler (cfc free)	$200.8K	6
Asthalin inhaler (cfc free)	$193.6K	7
Lanzol 30 capsules lansoprazole 30MG	$150.0K	3
Asthalin inhaler (cfc free) (salbutamolsulphate 100 MCG) .	$143.2K	5
Azee 500 tablet (azithromycin dihydrate500 MG) . (inv.qty.32520 Pack 1x3s=97560 nos	$137.8K	3
Flomist nasal spray (fluticasone propionate nasal suspension 50 MCG).	$136.0K	5
Flomist nasal spray (fluticasone propionate nasal suspension 50 MCG). (1x100 md)	$125.9K	5
Budesonide inhalation suspension 0.5MG/2ML ndc no. 69097-319-87 anda no. 205710 (inv.qty.5496 Pack 6x5x2 ML=164880	$114.9K	3
Lanzol 30 capsules lansoprazole 30MG inv qty 25200 Pack 3x10s 756000	$100.0K	2
Amlopres 5 MG TAB amlodipine	$100.0K	2

Capital Pharmacy imports 341 distinct pharmaceutical formulations. Showing top 15 by value. For full formulation-level data, contact TransData Nexus.

Import Portfolio — Top 2 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Lansoprazole	Gastrointestinal	$1.2M	24	0.4%	7
2	Budesonide	Respiratory	$1.1M	22	0.6%	13

Capital Pharmacy imports 2 pharmaceutical products across 2 categories into Oman totaling $2.3M.

Capital Pharmacy — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Capital Pharmacy, a division of Transworld for Marketing & Trading LLC, is a pharmaceutical distribution company based in Muscat, Oman. Established in 1998, the company has over 15 years of experience in delivering patient-oriented healthcare solutions across the Sultanate. Capital Pharmacy operates as a pharmaceutical importer and distributor, supplying a wide range of medicines, surgical, orthopedic, and allied products to clinics, pharmacies, and hospitals throughout Oman. The company emphasizes partnerships with renowned pharmaceutical manufacturers to provide quality healthcare products at reasonable prices.

2Distribution Network

Capital Pharmacy's distribution network is strategically designed to ensure efficient delivery of pharmaceutical products across Oman. The company's warehouse is located in the heart of Muscat at Ruwi, registered with the Ministry of Health (MoH) Oman, and complies with stringent regulations related to storage, temperature control, and logistics operations. Additionally, Capital Pharmacy operates a chain of pharmacies in prime locations throughout Muscat, Sohar, Barka, and Salalah, providing customers with quality medicines and excellent community pharmacist support. The company also utilizes its sister concern, Al Hashar Pharmacy LLC, for logistics and delivery services, ensuring timely supplies to pharmacies, clinics, hospitals, MoH stores, and various other health institutions.

3Industry Role

Capital Pharmacy plays a pivotal role in Oman's pharmaceutical supply chain as a primary wholesaler and distributor. By importing and supplying a diverse range of pharmaceutical products, the company ensures the availability of essential medicines and healthcare products across the country. Its partnerships with reputable international manufacturers and adherence to strict regulatory standards underscore its commitment to quality and reliability in the pharmaceutical sector.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Capital Pharmacy

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Capital Pharmacy's sourcing strategy exhibits a high degree of concentration, with a significant portion of its pharmaceutical imports originating from India. The company's total import value from India amounts to $2.3 million USD, encompassing 46 shipments and 341 unique formulations across two therapeutic categories. The top five imported products include Lansoprazole ($1.2 million, Rank #7, 0.4% share) and Budesonide ($1.1 million, Rank #13, 0.6% share). This concentration indicates a strategic choice to leverage India's robust pharmaceutical manufacturing capabilities and cost-effectiveness. However, such dependency on a single source may pose risks related to supply chain disruptions, currency fluctuations, and geopolitical factors. The shipment data reveals a stable relationship with Indian suppliers, as evidenced by the consistent import volumes and the presence of three verified Indian suppliers: CIPLA LIMITED ($7.2 million, 98.6% share), STRIDES PHARMA SCIENCE LIMITED ($100K, 1.4% share), and MANKIND PHARMA LIMITED ($2K, 0.0% share). This stability suggests a well-established and reliable sourcing arrangement.

2Supply Chain Resilience

Capital Pharmacy's supply chain resilience is influenced by its concentrated sourcing from India. The company's reliance on a limited number of suppliers may expose it to risks such as supply disruptions, regulatory changes, and logistical challenges. The absence of backup suppliers in the available data indicates a potential vulnerability in the supply chain. Additionally, the limited diversity in imported formulations suggests a focused product strategy, which may impact the company's ability to adapt to changing market demands. The shipping routes from India to Oman are well-established, but any disruptions in these routes could affect the supply chain. Regarding regulatory compliance, the key Indian suppliers—CIPLA LIMITED, STRIDES PHARMA SCIENCE LIMITED, and MANKIND PHARMA LIMITED—are recognized for adhering to international quality standards, including Good Manufacturing Practices (GMP). However, the data does not provide specific details on the suppliers' certifications, which are crucial for ensuring product quality and regulatory compliance.

Importing Pharmaceuticals into Oman — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Oman

1Regulatory Authority & Framework

In Oman, the Ministry of Health (MoH) is the primary regulatory authority overseeing the pharmaceutical sector. The MoH is responsible for ensuring the safety, efficacy, and quality of pharmaceutical products available in the country. Key legislation governing pharmaceutical imports includes the Pharmaceutical Law, which outlines the requirements for drug registration, importation, and distribution. The registration process involves assessing the product's purpose, country of origin, demand, and the presence of similar products in the market. This comprehensive regulatory framework ensures that only approved and safe pharmaceutical products are available to the public.

2Import Licensing & GMP

Import licensing in Oman requires pharmaceutical companies to obtain authorization from the MoH before importing medicines. This process ensures that imported products meet the country's regulatory standards. Good Manufacturing Practice (GMP) certificates from recognized bodies such as the European Union (EU), World Health Organization (WHO), or Pharmaceutical Inspection Co-operation Scheme (PIC/S) are essential for the importation of pharmaceutical products into Oman. These certifications confirm that the manufacturing facilities adhere to international quality standards, ensuring the safety and efficacy of the products. Additionally, wholesale distribution authorization is required for companies involved in the distribution of pharmaceutical products within Oman.

Capital Pharmacy — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Capital Pharmacy's product strategy focuses on two primary therapeutic categories: gastrointestinal and respiratory treatments. The company's top imported products, Lansoprazole and Budesonide, are commonly used in these therapeutic areas. This focus aligns with the prevalent health conditions in Oman, where gastrointestinal and respiratory diseases are significant health concerns. The demand for these products is driven by the need for effective treatments for conditions such as acid reflux, ulcers, asthma, and chronic obstructive pulmonary disease (COPD). By concentrating on these therapeutic areas, Capital Pharmacy aims to address critical healthcare needs and provide essential medications to the Omani population.

2Sourcing Profile

Capital Pharmacy's sourcing strategy is centered on importing generic pharmaceutical products from India, focusing on formulations that are in high demand within the Omani market. The company's preference for generic drugs allows it to offer cost-effective solutions to healthcare providers and patients. India's well-established pharmaceutical manufacturing industry, known for its adherence to international quality standards, makes it a reliable source for these products. This sourcing approach enables Capital Pharmacy to maintain a diverse product portfolio while ensuring affordability and accessibility for the Omani population.

Market Positioning

Seller's Guide — How to Become a Supplier to Capital Pharmacy

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to collaborate with Capital Pharmacy, given the company's established sourcing patterns and its focus on importing pharmaceutical products from India. Potential suppliers can explore opportunities to provide alternative formulations or additional products that complement Capital Pharmacy's existing portfolio, thereby filling gaps and meeting diverse patient needs. However, new suppliers must ensure compliance with Oman's regulatory requirements, including obtaining the necessary import licenses and GMP certifications, to establish a successful partnership.

TransData Nexus Research · Industry procurement practicesMar 2026

Frequently Asked Questions — Capital Pharmacy

What products does Capital Pharmacy import from India?

Capital Pharmacy imports 2 pharmaceutical products across 2 categories. Top imports: Lansoprazole ($1.2M), Budesonide ($1.1M).

Who supplies pharmaceuticals to Capital Pharmacy from India?

Capital Pharmacy sources from 3 verified Indian suppliers. The primary supplier is Cipla Limited (98.6% of imports, $7.2M).

What is Capital Pharmacy's total pharmaceutical import value?

Capital Pharmacy's total pharmaceutical import value from India is $2.3M, based on 46 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Capital Pharmacy focus on?

Capital Pharmacy imports across 2 categories. The largest: Gastrointestinal (52.2%), Respiratory (47.8%).

Get Full Capital Pharmacy Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. For current shipment-level data, contact TransData Nexus.